Multicenter Retrospective Analysis of Nivolumab Monotherapy Outcomes in Advanced Renal Cell Carcinoma by the Spanish Genitourinary Oncology Group - Scorecard - MDSpire

Multicenter Retrospective Analysis of Nivolumab Monotherapy Outcomes in Advanced Renal Cell Carcinoma by the Spanish Genitourinary Oncology Group

  • By

  • Natalia Fernández-Díaz

  • María Mateos-González

  • Ana Pertejo-Fernández

  • Juan Diego Cacho-Lavín

  • María José Juan-Fita

  • Isabel Chirivella-González

  • Mikel Arruti-Ibarbia

  • Ovidio Fernández-Calvo

  • Natalia Fernández-Núñez

  • María José Méndez-Vidal

  • Martín Lázaro-Quintela

  • Aurea Molina-Díaz

  • Nieves Del Pozo-Alonso

  • Olatz Etxaniz-Ulazia

  • Silvia Margarita García-Acuña

  • Yoel Z. Betancor

  • Ainara Azueta-Etxebarria

  • Ana Calatrava-Fons

  • Helena Lombardía-Rodríguez

  • Lorena Alarcón-Molero

  • Leire Etxegarai-Ganboa

  • Abraham Antón-Cameselle

  • José Antonio Bello-Giz

  • Carlos Manuel Neira-De Paz

  • Teresa Cabaleiro

  • Teresa González-Serrano

  • José Antonio Ortiz-Rey

  • Felipe Sacristán-Lista

  • Silvia García-Rubín

  • Elisa Ortega

  • Cristina Carrato-Moñino

  • Santiago Aguín-Losada

  • Luis León-Mateos

  • Jorge García-González

  • Álvaro Pinto-Marín

  • Ignacio Duran

  • Rafael López-López

  • Urbano Anido-Herranz

  • Juan Ruiz-Bañobre

  • November 28, 2025

  • 0 min

Share

Clinical Scorecard: Multicenter Retrospective Analysis of Nivolumab Monotherapy Outcomes in Advanced Renal Cell Carcinoma by the Spanish Genitourinary Oncology Group

At a Glance

CategoryDetail
ConditionAdvanced Renal Cell Carcinoma (aRCC)
Key MechanismsNivolumab is an anti-PD-1 antibody that enhances immune response against tumor cells by blocking the PD-1 pathway.
Target PopulationPatients with advanced renal cell carcinoma previously treated with anti-angiogenic agents
Care SettingRoutine clinical practice in multiple Spanish medical centers

Key Highlights

  • Nivolumab demonstrated a significant overall survival benefit in aRCC patients previously treated with anti-angiogenic therapies.
  • The study included 222 patients treated with nivolumab in second line or beyond, reflecting real-world clinical practice.
  • Most patients had good performance status (ECOG 0-1) and clear cell histology, with common metastasis sites including lungs and lymph nodes.

Guideline-Based Recommendations

Diagnosis

  • Histologically confirmed advanced renal cell carcinoma.
  • Assessment of performance status (ECOG) and IMDC risk score for prognosis.

Management

  • Nivolumab monotherapy is recommended for aRCC patients previously treated with anti-angiogenic agents.
  • Dosing regimens include 3 mg/kg every 2 weeks, 240 mg every 2 weeks, or 480 mg every 4 weeks intravenously until progression or unacceptable toxicity.

Monitoring & Follow-up

  • Tumor response assessment every 10 ± 2 weeks using RECIST v1.1 criteria.
  • Monitoring for disease progression and treatment-related toxicity.
  • Regular evaluation of laboratory parameters and corticosteroid use within 30 days prior to treatment initiation.

Risks

  • Potential for disease progression despite treatment.
  • Unacceptable toxicity leading to treatment discontinuation.

Patient & Prescribing Data

222 patients with advanced renal cell carcinoma treated in routine clinical practice in Spain, median age 65 years, predominantly male, mostly ECOG 0-1, and mostly clear cell histology.

Nivolumab was administered as second-line therapy or beyond, showing real-world efficacy consistent with clinical trial data.

Clinical Best Practices

  • Select patients with confirmed aRCC and prior anti-angiogenic therapy for nivolumab treatment.
  • Use standardized dosing schedules and monitor response regularly with RECIST criteria.
  • Consider patient performance status and IMDC risk score when evaluating prognosis and treatment planning.
  • Ensure ethical approval and informed consent in retrospective and prospective studies.

References

Original Source(s)

Multicenter Retrospective Analysis of Nivolumab Monotherapy Outcomes in Advanced Renal Cell Carcinoma by the Spanish Genitourinary Oncology Group

  • by Natalia Fernández-Díaz, María Mateos-González, Ana Pertejo-Fernández, Juan Diego Cacho-Lavín, María José Juan-Fita, Isabel Chirivella-González, Mikel Arruti-Ibarbia, Ovidio Fernández-Calvo, Natalia Fernández-Núñez, María José Méndez-Vidal, Martín Lázaro-Quintela, Aurea Molina-Díaz, Nieves Del Pozo-Alonso, Olatz Etxaniz-Ulazia, Silvia Margarita García-Acuña, Yoel Z. Betancor, Ainara Azueta-Etxebarria, Ana Calatrava-Fons, Helena Lombardía-Rodríguez, Lorena Alarcón-Molero, Leire Etxegarai-Ganboa, Abraham Antón-Cameselle, José Antonio Bello-Giz, Carlos Manuel Neira-De Paz, Teresa Cabaleiro, Teresa González-Serrano, José Antonio Ortiz-Rey, Felipe Sacristán-Lista, Silvia García-Rubín, Elisa Ortega, Cristina Carrato-Moñino, Santiago Aguín-Losada, Luis León-Mateos, Jorge García-González, Álvaro Pinto-Marín, Ignacio Duran, Rafael López-López, Urbano Anido-Herranz, Juan Ruiz-Bañobre

  • November 28, 2025

Related Content

Recurrent IDH-mutant astrocytoma WHO grade 4 diagnosed during pregnancy: case report with literature review

Synthetic short RNA in cancer

Management of toxicities from antibody – drug conjugates in breast cancer